IFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab in

Affiliation auteurs!!!! Error affiliation !!!!
TitreIFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab in
Type de publicationJournal Article
Year of Publication2019
AuteursZalcman G., Toffart A.C, Flandin A-C.Madroszyk, Molinier O., Dayen C., Egenod T., Dixmier A., E. Leprieur G, Masson P., Cloarec N., Thibonnier L., Favier L., Debieuvre D., Mazieres J., Van Hulst S., Pichon E., Amour E., Morin F., Souquet P-J.
JournalANNALS OF ONCOLOGY
Volume30
Pagination658
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN0923-7534